Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents
S Miyamoto, N Miyake, LF Jarskog… - Molecular …, 2012 - nature.com
Since the introduction of chlorpromazine and throughout the development of the new-
generation antipsychotic drugs (APDs) beginning with clozapine, the D 2 receptor has been …
generation antipsychotic drugs (APDs) beginning with clozapine, the D 2 receptor has been …
Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents
S Miyamoto, N Miyake, LF Jarskog… - Molecular …, 2012 - go.gale.com
Since the introduction of chlorpromazine and throughout the development of the new-
generation antipsychotic drugs (APDs) beginning with clozapine, the [D. sub. 2] receptor has …
generation antipsychotic drugs (APDs) beginning with clozapine, the [D. sub. 2] receptor has …
[PDF][PDF] Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents
S Miyamoto, N Miyake, LF Jarskog… - Molecular …, 2012 - researchgate.net
Schizophrenia is a chronic and debilitating disorder with a lifetime prevalence near 1%. 1 It
is characterized by positive, negative, cognitive and affective symptoms, and may arise from …
is characterized by positive, negative, cognitive and affective symptoms, and may arise from …
Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.
S Miyamoto, N Miyake, LF Jarskog… - Molecular …, 2012 - search.ebscohost.com
Since the introduction of chlorpromazine and throughout the development of the new-
generation antipsychotic drugs (APDs) beginning with clozapine, the D< sub> 2 receptor …
generation antipsychotic drugs (APDs) beginning with clozapine, the D< sub> 2 receptor …
Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents
S Miyamoto, N Miyake, LF Jarskog… - Molecular …, 2012 - pubmed.ncbi.nlm.nih.gov
Since the introduction of chlorpromazine and throughout the development of the new-
generation antipsychotic drugs (APDs) beginning with clozapine, the D (2) receptor has …
generation antipsychotic drugs (APDs) beginning with clozapine, the D (2) receptor has …
[PDF][PDF] Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents
S Miyamoto, N Miyake, LF Jarskog… - Molecular …, 2012 - academia.edu
Schizophrenia is a chronic and debilitating disorder with a lifetime prevalence near 1%. 1 It
is characterized by positive, negative, cognitive and affective symptoms, and may arise from …
is characterized by positive, negative, cognitive and affective symptoms, and may arise from …
Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.
S Miyamoto, N Miyake, LF Jarskog… - Molecular …, 2012 - europepmc.org
Since the introduction of chlorpromazine and throughout the development of the new-
generation antipsychotic drugs (APDs) beginning with clozapine, the D (2) receptor has …
generation antipsychotic drugs (APDs) beginning with clozapine, the D (2) receptor has …
[引用][C] Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents
S MIYAMOTO - Mol. Psychiatry, 2012 - cir.nii.ac.jp
Pharmacological treatment of schizophrenia : a critical review of the pharmacology and
clinical effects of current and future therapeutic agents | CiNii Research CiNii 国立情報学 …
clinical effects of current and future therapeutic agents | CiNii Research CiNii 国立情報学 …
[引用][C] Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents
S MIYAMOTO, N MIYAKE, LF JARSKOG… - Molecular …, 2012 - pascal-francis.inist.fr
Pharmacological treatment of schizophrenia: a critical review of the pharmacology and
clinical effects of current and future therapeutic agents CNRS Inist Pascal-Francis CNRS …
clinical effects of current and future therapeutic agents CNRS Inist Pascal-Francis CNRS …
[PDF][PDF] Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents
S Miyamoto, N Miyake, LF Jarskog… - Molecular …, 2012 - academia.edu
Schizophrenia is a chronic and debilitating disorder with a lifetime prevalence near 1%. 1 It
is characterized by positive, negative, cognitive and affective symptoms, and may arise from …
is characterized by positive, negative, cognitive and affective symptoms, and may arise from …